Lung Disease is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Lung Disease have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Lung Disease compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lung Disease overview
Lung diseases are infections or disorders that affect the lungs and can cause breathing problems. Some of the common lung diseases are asthma, pneumothorax or atelectasis, bronchitis, COPD, lung cancer, pneumonia, pulmonary edema. Cigarette smoking, secondhand smoke, asbestos, radon gas, air pollution, chemicals such as uranium, beryllium, vinyl chloride, and arsenic are risk factors responsible for causing lung disease. Major symptoms include chronic cough and shortness of breath. Treatment options corticosteroids, anti-fibrotic and cytotoxic drugs, biologic drugs, pulmonary rehabilitation, oxygen therapy, lung transplant.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Lung Disease, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
